Literature DB >> 28003751

Effect of dexmedetomidine on hippocampal neuron development and BDNF-TrkB signal expression in neonatal rats.

Jie Lv1, Wei Ou1, Xiao-Hua Zou1, Yin Yao1, Jin-Li Wu1.   

Abstract

The study aimed to explore the effect of dexmedetomidine (DEX) on hippocampal neuron development process and on molecular expression of brain-derived neurotrophic factor (BDNF)-tyrosine receptor kinase B (TrkB) signaling pathway in neonatal rats. The hippocampal neuron cells were isolated from newborn neonatal rats and cultured in vitro. One control group and three treated groups with 1, 10, and 100 μmol/L DEX were used for the study. Cell activity and apoptosis were detected by the MTT and terminal deoxynucleotidyl transferase-mediated biotinylated uridine triphosphate (UTP) nick end labeling assays. The synaptophysin (SYN) and postsynaptic density 95 (PSD95) were detected by quantitative polymerase chain reaction. There was no difference in the viability of neuron cells among the different dose groups of DEX and the control group during days 2-10 (P>0.05). Compared to the control group, there was no significant difference (P>0.05) in the expressions of SYN and PSD95 in the groups treated with 1 and 10 μmol/L DEX, whereas significant difference in the expression was observed in the group treated with 100 μmol/L DEX (P<0.01). Compared with the control group, the expression of BDNF was significantly upregulated (P<0.05) in the group treated with 100 μmol/L DEX. There were no significant differences in TrkB expression among the four groups. The expression of p-N-methyl-D-aspartate receptor increased with an increase in the concentration of DEX; however, only the high dose revealed a significant upregulation compared with the control group. The neuroprotective effect of DEX may be achieved by upregulating the expression of BDNF and phosphorylation level of N-methyl-D-aspartate receptor.

Entities:  

Keywords:  BDNF-TrkB; development; dexmedetomidine; hippocampal neuron

Year:  2016        PMID: 28003751      PMCID: PMC5158139          DOI: 10.2147/NDT.S120078

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

As an important member of the nerve factor family, brain-derived neurotrophic factor (BDNF) regulates and maintains the development and function of the nervous system by promoting the proliferation and differentiation of nerve cells. Synapse is an important way of transferring information between neurons, and its structure consists of the front membrane, the gap, and the posterior membrane. Neurons form complex neural networks in the form of synapses and play an important role in the physiological and pathological processes of the central nervous system. After the specific binding between BDNF and tyrosine receptor kinase B (TrkB), the conformation changes, which lead to the phosphorylation of downstream key kinase, promote the expression of BDNF in neurons and dendrites, and activate the BDNF-TrkB signaling pathway. BDNF is first transported to the presynaptic neurons where it displays its regulatory function. Therefore, BDNF plays an important role in presynaptic regulation.1–3 Dexmedetomidine (DEX) is a type of α2-adrenergic receptor agonist with the main ingredient DEX hydrochloride injection, the α2-adrenergic receptor affinity is eight times that of clonidine.4–6 DEX is widely used as an auxiliary drug in clinical anesthesia. With the application of general anesthesia in clinics, increasing attention has been given to central toxic effects of general anesthetics in recent years, especially on the development of neurons, which is of great significance in infants.7 This study explored the effect of DEX on the expression of genes involved in the neonatal hippocampal neuron development and on the expression of molecules involved in the BDNF-TrkB signaling pathway by isolating and culturing neurons in the hippocampus of neonatal rats. The synaptophysin (SYN) was distributed in the presynaptic membrane and postsynaptic density 95 (PSD95) was located in the postsynaptic structure. These synapse-specific protein markers may directly or indirectly reflect the synaptic activity, morphological changes, and the biological function of the synapse.6,8 We analyzed the activity and apoptosis of neurons in the hippocampus of neonatal rats, analyzed the effect of DEX on BDNF-TrkB signal pathway, and investigated the molecular mechanism of the biological effects that DEX exerts through BDNF-TrkB signaling pathway.

Materials and methods

Experimental animals

Specific pathogen-free (SPF) grade Sprague Dawley pregnant rats were purchased from Shanghai Silaike Experimental Animals Inc. (Shanghai, People’s Republic of China). The mean (± standard deviation) rat weight was 250 (±30 g), and they were fed with standard pellets in standard animal cages (three animals per cage). The feeding room had good ventilation and natural lighting. Room temperature was maintained at 18°C–25°C. The primary hippocampal neurons were isolated from neonatal rats within 24 hours after delivery. The study protocol was approved by the Institutional Review Board of the Guizhou Medical University Affiliated Hospital. All animal handling procedures were carried out in accordance with the protocols of the animal care guidelines of the Institutional Animal Care Committee.

Main reagents and instruments

The following reagents and chemicals were used for the experiments: Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine serum, Neurobasal®, and B27 additives (Thermo Fisher Scientific, Waltham, MA, USA); L-glutamine (Sigma-Aldrich Co., St Louis, MO, USA); DEX (Jiangsu Hengrui Medicine Co., Lianyungang, People’s Republic of China); terminal deoxynucleotidyl transferase-mediated biotinylated uridine triphosphate (UTP) nick end labeling (TUNEL) kit (Vazyme Biotech Co., Piscataway, NJ, USA); MTT detection kit (Beijing Boosen Biological Technology Co., Beijing, People’s Republic of China); RNA purification kit (QIAGEN Translational Medicine Co., Suzhou, People’s Republic of China); reverse transcription kit (Applied Biosystems Co., Foster City, CA, USA); SYBR Green real-time PCR premixed liquid (Applied Biosystems Co.); ReadyPrep protein extraction kit (Bio-Rad Laboratories Inc., Hercules, CA, USA); MAP-2 monoclonal antibody (Santa Cruz Biotechnology Inc., Dallas, TX, USA); BDNF, TrkB, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) monoclonal antibody (Abcam, Cambridge, UK); p-N-methyl-D-aspartate receptor (p-NMDAR) and NMDAR-2B monoclonal antibody (CST Co., Danvers, MA, USA); horseradish peroxidase (HRP)-labeled secondary antibody (Wuhan Boster Bioengineering Limited Co., Wuhan, People’s Republic of China). The following instruments were used: optical microscope (OLYMPUS BX53), CO2 incubator (Thermo Scientific Series 8000), nucleic acid quantitative instrument (Nanodrop 2000), and fluorescence quantitative PCR detection system (Applied Biosystems 7500).

Isolation and culture of hippocampal neurons in neonatal rats

The neonatal rats were sacrificed within 24 hours after delivery by cervical dislocation. Then the neonatal rats were placed in 75% ethanol for 2 minutes. We removed the skin and skull of the rats’ head and took out the whole brain. With the help of an anatomical microscope, we carefully removed the olfactory bulb, septum, thalamus, and hypothalamus. We then peeled off the dural and choroid plexus and took out the hippocampus tissue under the cerebral cortex into pre-cold sterile phosphate buffered saline (PBS). The hippocampus tissue was cut into pieces with ophthalmology scissors, and then 0.25% trypsin/0.02% ethylene diamine tetra acetic acid (EDTA) was added and digested at 37°C for 5 minutes to prepare single cell suspension. After removing the supernatant by centrifugation, the cell precipitate was suspended in DMEM complete culture medium (containing 2% B27, 1% glutamine, 10% fetal bovine serum), inoculated in cell culture bottle, and cultured at 37°C in a 5% CO2 incubator. After adherent for 6–8 hours, the cells were transferred to Neurobasal medium (for use immediately, containing 2% B27, 1% glutamine, and 100 IU/mL penicillin).

Western blot

After cleaning with PBS, the total protein was extracted using the protein extraction kit and the concentration was quantified by the bicinchoninic acid method. After the protein sample was subjected to substrate-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the gel was dipped in the transfer buffer balance for 10 minutes and transferred to the membrane for 45–60 minutes. Then the polyvinylidene difluoride (PVDF) membrane was rinsed for 10–15 minutes with tris-buffered saline (TBS), and proper dilution of antibody (containing 1% of skim milk diluted with TBS containing Tween-20 [TBST]) was added and incubated at room temperature for 2 hours. Then the membrane was rinsed three times (each for 5–10 minutes) with TBST and was incubated with HRP-labeled secondary antibody, which was diluted with TBST containing 0.05% of skim milk (1:10,000). Again, the membrane was rinsed three times with TBST, each for 5–10 minutes. The experimental results were preserved by exposure and photographic processing. Quantity one Version 4.62 software was used to measure the gray value of molecular bands (quantitative method of strip track). On the quantitative basis, the semi-quantitative value of target protein/reference protein was used for statistical analysis.

q-PCR detection

Total RNA was extracted according to the manufacturer’s instructions and concentration and purity were detected by Nanodrop 2000. According to the reverse transcription kit instructions, total RNA was reverse transcribed to cDNA. Real-time PCR was used to detect related genes. To request for target gene mRNA sequences in the NCBI database, we designed the real-time PCR primers, whose specific sequences were as follows: SYN (NM_008596) forward: CGCACCTCGGACAAGTCTC, reverse: CCCGAAGGCGAAAATAGCAAA; Dlg4 (PSD95, NM_001109752) forward: TCCGGGAGGTGACCCATTC; reverse: TTTCCGGCGCATGACGTAG. PCR reaction parameters were as follows: pre-denaturation at 94°C for 10 minutes, denaturation at 95°C for 10 seconds, annealing temperature according to the melting temperature of primer, reaction time of 20 seconds, extend at 72°C for 30 seconds with 40 cycles.

Statistical analysis

Mean and standard deviation (SD) were used to summarize continuous variables. One-way analysis of variance was used to determine the differences among groups. P-value <0.05 was considered to be statistically significant. All analyses were performed using SPSS software, Version 17.0.

Results

Culture of hippocampal neurons in vitro

The hippocampal neurons were separated from the rats born within 24 hours and cultured in vitro. When observed under inverted microscope, about 80% of the neurons began to stick to the wall after 5–6 hours and were circular or elliptic in shape. The cells continued to grow long after 10 hours with small bumps. After 3 days, cell volume increased with multiple extensions for shape or spindle. After 20 days of culture, nerve cells began to appear degenerated, with granular-vacuolar degeneration in cytoplasm, degradation, and nuclear pyknosis. The neurons were identified by neuron markers such as MAP-2 in the cells growing on the glass slide. The MAP-2-positive cells, cell body, and bumps were dyed brown. By observing the ratio of the number of MAP-2-positive cells to the total number of cells marked by Hoechst stain, its purity was found to be 90.2%±1.7% when cultured for 7 days.

Effect of DEX on the development of hippocampus neuron cells

The animals were divided into four groups as follows: control group (Ctrl), treated group cultured with 1 μmol/L DEX (group 1), treated group cultured with 10 μmol/L DEX (group 10), and treated group cultured with 100 μmol/L DEX (group 100). MTT and TUNEL methods were used to determine cell activity and apoptosis. The results of the MTT test showed that there was no difference in the activity and apoptosis curves of neuron cells among the different DEX-treated groups and the control group during 2–10 days (P<0.05; Figure 1A). Cells that grew on the glass slide were prepared and detected by fluorescence and counted by Image-Pro Plus 6.0 software. There were no significant differences among the four groups with regard to the number of positive cells (P>0.05; Figure 1B).
Figure 1

Cell activity and apoptosis were detected by MTT (A) and TUNEL (B) assays.

Abbreviations: Ctrl, control group; TUNEL, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling; UTP, uridine triphosphate.

The expressions of SYN and PSD95 were detected by q-PCR to explore the effect of DEX on the development of hippocampal neurons. Compared with the control group, the expressions of SYN and PSD95 exhibited no significant differences (P>0.05) in the groups treated with 1 or 10 μmol/L DEX, whereas a significant difference with regard to the expression was observed in the group treated with 100 μmol/L DEX (P<0.01; Figure 2).
Figure 2

The relative expression and quantitative curves of SYN (A and C) and PSD95 (B and D) in the four groups.

Abbreviations: Ctrl, control group; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RFU, relative fluorescence unit; SYN, synaptophysin.

Effect of DEX on the expression of signaling molecules in the BDNF-TrkB signal pathway

Western blot analysis was used to analyze the effect of DEX on the expression and phosphorylation level of BDNF, TrkB, and N-methyl-D-aspartate receptor (NMDA). As shown in Figure 3, the expression of BDNF was positively correlated with the appropriate concentration of DEX. Compared with the control group, the expression of BDNF was significantly upregulated in the group treated with 100 μmol/L DEX (P<0.05). There were no significant differences in TrkB expression among the four groups. The expression of p-NMDAR increased with the increasing concentration of DEX; however, only the high dose revealed a significant upregulation compared with the control group.
Figure 3

The expression of BDNF and TrkB in the four groups by the Western blot: (A) the electrophoretogram of Western blot; (B) the bar charts of the expression of BDNF and TrkB.

Note: *Indicates the significance compared to the control group.

Abbreviations: BDNF, brain-derived neurotrophic factor; Ctrl, control group; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NMDAR, N-methyl-D-aspartate receptor.

Discussion

General anesthetics usually act by rendering the subject unconscious and by blocking neurotransmission via exciting gamma aminobutyric acid receptor or antagonizing NMDA receptor.9 Although general anesthesia has wide application in clinics, further reflecting its superiority, people are increasingly concerned about its safety. The NMDA antagonists such as MK801 and ketamine might exhibit neurotoxicity.10 The combination of isoflurane and midazolam caused neuronal apoptosis in neonatal mice.11 These reports led to concerns about safety of ketamine in pediatric anesthesia. Previously, anesthesiology considered that by avoiding hypoxia of brain tissue in the anesthesia process, one could reduce the influence of anesthetic drugs on the intelligence development of infants.12 However, recent research showed the peak period of central nerve growth and development in animals occurred within a certain period before and after their birth, during which amplification of a large number of nerve cells of the animal’s brain tissue was observed, with a large number of dendrites connecting with synapses. During this period, the central nervous system was sensitive to the peripheral microenvironment and vulnerable to stimulants affecting its normal development, which led to long-term mental and behavioral abnormalities.13,14 Medetomidine is an agonist for central α2 adrenoceptor, which is a mixture of sinistral medetomidine and DEX, and sinistral DEX has no pharmacological effects.15,16 DEX is a dextro isomer of medetomidine. DEX is used as a sedative and analgesic in clinical setting, and its sensitivity to central α2 adrenoceptor is higher than that of medetomidine.17,18 In order to reduce the harmful effects of general anesthesia on the nervous system, anesthetic drugs such as ketamine and propofol can be combined with DEX for producing anesthesia, and this approach has become a trend in clinical setting. This study explored the effect of DEX on hippocampal neuronal development in neonatal rats and on the expression of molecules involved in the BDNF-TrkB signaling pathway through the separation and culturing of hippocampal neurons of the neonatal rats, in order to provide more detailed experimental evidence for the clinical application of DEX. Hippocampus is an important part of the brain tissue, and its structure and boundary are relatively clear, enabling easy dissection and separation. These advantages make it an ideal tissue for neural pharmacology experiments. In the present study, we selected neonatal rats and isolated hippocampal neuron cells for in vitro culture. Most of the neurons began to adhere to the wall within 6 hours. After culturing for 3 days, a significantly increased cell volume was observed, and the cell bodies had grown a number of protuberances. After continuous culture for 20 days, the nerve cells started to degenerate, with the appearance of granular vacuoles, degeneration of protuberances, and nuclear pyknosis. Therefore, we tried to choose early generation of cells for this experiment. MAP-2 is a neuronal marker, and by observing the ratio of the number of MAP-2-positive labeled cells to the total number of Hoechst labeled cells, the purity of hippocampal neurons reached 90% after culturing for 7 days. Synapse-specific protein markers such as SYN and PSD95 directly or indirectly reflected the synaptic activity, morphology changes, and synaptic biological function. Neuronal development state was indirectly shown through determining the expression of SYN and PSD95. After using different concentrations of DEX, hippocampus neuron cell viability and apoptosis were analyzed in neonatal rats. The differences in the expression of SYN and gap43 were detected by real-time PCR, in order to explore the developmental situation of hippocampal neurons. The results of the MTT assay showed that after treating with different doses of DEX, the neuron activity and apoptosis curve during the 2–10 days showed no statistical significance compared with the control group. There was no statistical significance in the number of positive cells between the DEX treatment groups (1, 10, and 100 μmol/L) and the control group. This result indicated that DEX itself had no toxicity on neural cells, which was consistent with previous studies.19 DEX reduced hypoxia/reoxygenation-induced apoptosis through the inhibition of gap junctions activity by reducing Cx32 protein levels.20 Neuroprotective effect of DEX attenuates isoflurane-induced cognitive impairment through antioxidant, anti-inflammatory, and anti-apoptosis properties in aging rats.21 However, although DEX is neuroprotective at clinical doses, high cumulative doses and concentrations induce neuroapoptosis in vivo and in vitro, respectively.22 The combination of BDNF and TrkB led to a conformational change and further contributed to the phosphorylation of downstream key kinases. It has been confirmed that BDNF-TrkB signaling pathway was able to activate important pathways like MEK/ERK, PI3K/Akt, and PLC gamma 1 signaling pathways.23,24 Our experiment analyzed the effect of DEX on BDNF-TrkB signaling pathway and its downstream effector molecules associated with NMDA receptor expression and the change of phosphorylation levels. The results indicated that the BDNF expression level was positively related to DEX concentration. After treatment with 100 μmol/L DEX, the BDNF expression level increased significantly (P<0.05). There was no correlation between the TrkB expression level and DEX treatment. There was no statistical significance among the groups with regard to the TrkB expression levels after treatment with different concentrations of DEX. The expression level of p-NMDAR showed an upward trend after DEX treatment. The variation in its background expression level exhibited no statistical significance, indicating that DEX directly or indirectly affected the activation of NMDAR, but not the expression level of NMDAR to participate in the signaling pathway.
  22 in total

Review 1.  Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations.

Authors:  M Mahmoud; K P Mason
Journal:  Br J Anaesth       Date:  2015-08       Impact factor: 9.166

2.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

Authors:  C Ikonomidou; F Bosch; M Miksa; P Bittigau; J Vöckler; K Dikranian; T I Tenkova; V Stefovska; L Turski; J W Olney
Journal:  Science       Date:  1999-01-01       Impact factor: 47.728

3.  Hyperactivation of BDNF-TrkB signaling cascades in human hypothalamic hamartoma (HH): a potential mechanism contributing to epileptogenesis.

Authors:  Suzan Semaan; Jie Wu; Yan Gan; Yu Jin; Guo-Hui Li; John F Kerrigan; Yong-Chang Chang; Yao Huang
Journal:  CNS Neurosci Ther       Date:  2014-10-13       Impact factor: 5.243

4.  A prospective study comparing the onset and analgesic efficacy of different concentrations of levobupivacaine with/without dexmedetomidine in young children undergoing caudal blockade.

Authors:  Ying-Jun She; Guan-Tu Xie; Yong-Hong Tan; Xiao-Hua Kuang; Gao-Feng Yu; Guo-Hua Lian; Xing-Rong Song
Journal:  J Clin Anesth       Date:  2014-11-21       Impact factor: 9.452

5.  Echocardiographic evaluation of the effects of dexmedetomidine on cardiac function during total intravenous anaesthesia.

Authors:  S H Lee; Y S Choi; G R Hong; Y J Oh
Journal:  Anaesthesia       Date:  2015-04-28       Impact factor: 6.955

6.  Dexmedetomidine-Induced Neuroapoptosis Is Dependent on Its Cumulative Dose.

Authors:  Jia-Ren Liu; Koichi Yuki; Chongwha Baek; Xiao-Hui Han; Sulpicio G Soriano
Journal:  Anesth Analg       Date:  2016-10       Impact factor: 5.108

7.  Hydrogen sulfide inhibits homocysteine-induced endoplasmic reticulum stress and neuronal apoptosis in rat hippocampus via upregulation of the BDNF-TrkB pathway.

Authors:  Hai-Jun Wei; Jin-Hua Xu; Man-Hong Li; Ji-Ping Tang; Wei Zou; Ping Zhang; Li Wang; Chun-Yan Wang; Xiao-Qing Tang
Journal:  Acta Pharmacol Sin       Date:  2014-04-21       Impact factor: 6.150

8.  Dexmedetomidine attenuates isoflurane-induced cognitive impairment through antioxidant, anti-inflammatory and anti-apoptosis in aging rat.

Authors:  Xiaoning Wang; Binjiang Zhao; Xue Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model.

Authors:  Soon-Tae Lee; Kon Chu; Keun-Hwa Jung; Jin Hee Kim; Ji-Young Huh; Hyejin Yoon; Dong-Kyu Park; Ji-Yeon Lim; Jeong-Min Kim; Daejong Jeon; Hoon Ryu; Sang Kun Lee; Manho Kim; Jae-Kyu Roh
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

10.  BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms.

Authors:  Q Ren; M Ma; C Yang; J-C Zhang; W Yao; K Hashimoto
Journal:  Transl Psychiatry       Date:  2015-10-27       Impact factor: 6.222

View more
  4 in total

1.  Dexmedetomidine mitigates sevoflurane-induced cell cycle arrest in hippocampus.

Authors:  Li-Jun Bo; Pei-Xia Yu; Fu-Zhen Zhang; Zhen-Ming Dong
Journal:  J Anesth       Date:  2018-08-20       Impact factor: 2.078

Review 2.  Update on the Mechanism and Treatment of Sevoflurane-Induced Postoperative Cognitive Dysfunction.

Authors:  Cong-Mei Wang; Wei-Can Chen; Yan Zhang; Shu Lin; He-Fan He
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

3.  Dexmedetomidine mitigates isoflurane-induced neurodegeneration in fetal rats during the second trimester of pregnancy.

Authors:  Zhi-Yuan Su; Qing Ye; Xian-Bao Liu; Yu-Zhong Chen; Hong Zhan; Shi-Yuan Xu
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

4.  Effects and mechanism of dexmedetomidine on neuronal cell injury induced by hypoxia-ischemia.

Authors:  Ya-Jun Liu; Duan-Yu Wang; Yong-Jian Yang; Wei-Fu Lei
Journal:  BMC Anesthesiol       Date:  2017-08-30       Impact factor: 2.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.